Lung Cancer Trials Ask AI to find trials
CompletedPhase 1NCT00456833
Official study title

Combination of RAD001 and Erlotinib in Patients With Advanced Non Small Cell Lung Cancer Previously Treated Only With Chemotherapy

Study summary

This study aims to assess the value of combined treatment with RAD001 and erlotinib in patients with advanced Non Small Cell Lung Cancer treated only with chemotherapy as systemic therapy.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedRAD001 and erlotinib

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Dec 21, 2020 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 1

Interventional

Where is it offered?14 U.S. locations

Locations may change over time.

Who runs it?Novartis Pharmaceuticals

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 1
Sponsor
Novartis Pharmaceuticals
Interventions being studied
Drug: RAD001; Drug: erlotinib
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Treatment approach
Chemotherapy→
Study topics
After prior treatment→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Age over 18 years
  • Advanced Non Small Cell Lung Cancer which is not responding to chemotherapy treatment including either cisplatin or carboplatin
  • Only 1-2 previous chemotherapy regimens for advanced disease
  • More than 2 weeks from previous surgery, radiation or chemotherapy
  • Ability to perform normal daily functions
Reasons someone may not be able to joinExclusion criteria
  • Chronic steroid treatment
  • Prior treatment with EGFR inhibitors
  • Active bleeding conditions, skin conditions, gastrointestinal disorders, mouth ulcers, eye conditions or other severe medical conditions
  • Other cancers within the past 2 years
  • Pregnant or breastfeeding women Other protocol-defined inclusion/

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Novartis Investigative SiteAtlanta, Georgia
  • Novartis Investigative SiteChicago, Illinois
  • Novartis Investigative SiteBoston, Massachusetts
  • Novartis Investigative SiteRochester, Minnesota
  • Novartis Investigative SiteNashville, Tennessee
  • Novartis Investigative SiteHouston, Texas
  • Novartis Investigative SiteMadison, Wisconsin
  • Novartis Investigative SiteRichmond, British Columbia
  • Novartis Investigative SiteToronto, Ontario
  • Novartis Investigative SiteMontreal, Quebec
  • Novartis Investigative SiteHerlev
  • Novartis Investigative SiteSaint-Herblain Cédex

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Dec 21, 2020. Always confirm current availability with the study team.

View original record ↗